Brian Druker: "Anatomy of a Breakthrough in Targeted Cancer Treatments" | Talks at Google

source: Talks at Google     2016年3月25日
Brian Druker, winner of the Lasker Prize and Director of the Knight Cancer Institute, is one of the developers of Gleevec, a triumph of rational, science-driven drug design and targeted cancer therapy. Originally developed to treat chronic myeloid leukemia, Gleevec is now used in more than 10 indications by hundreds of thousands of adults and children each year.
The Knight Cancer Institute, which Brian leads, is devoted to development of personalized cancer therapies. Supported by a recent billion dollar fundraising effort and state bond measure, its new focus is the early detection of cancer.
Moderated by Vik Bajaj.